Answers · Audits & Portfolio Pruning
How do you evaluate a patent portfolio you are thinking of acquiring?
Updated June 2026
The short answer
Run six checks: legal status and chain of title, claim strength against the products that matter, remaining life and fee burden, geographic coverage, encumbrances such as existing licenses and liens, and validity risk. Published guidance commonly puts IP due diligence at 2 to 6 weeks for a mid-market deal.
The work splits cleanly: counsel verifies title, encumbrances, and validity questions, while analysts map claims to products, position the portfolio in the competitive landscape, and build the valuation. Buying on patent count without both halves is how acquirers overpay.
The six checks
Legal status and title first, because everything else assumes the seller owns live assets: confirm each patent is granted or pending as represented, fees are paid, and every inventor assignment is recorded without gaps. Claim strength is the heart of the evaluation: read the independent claims against the products you care about, yours, the seller's, and competitors', because a portfolio's value lives in what its claims actually cover, not in its count. Remaining life and fee burden set the economics: a patent with 4 years left is a different asset than one with 15, and US maintenance fees at 3.5, 7.5, and 11.5 years plus foreign annuities are a real liability you are also acquiring.
Geographic coverage tells you where the protection exists; a US-only portfolio cannot support a global product strategy. Encumbrances are the silent value-killers: existing licenses (including broad cross-licenses granted in the seller's past disputes), liens, government march-in rights from funded research, and standards commitments can leave you owning a patent everyone important is already free to practice. Validity risk rounds it out: prior art searching on the crown-jewel assets, since a flagship patent that would not survive a challenge anchors no deal.
Where acquisitions go wrong
The recurring failures are predictable. Paying for count, where 300 patents turn out to be 30 families of which 5 matter. Discovering after closing that key assets were licensed to your main competitor in a settlement years ago. Inventor-assignment gaps, common in startups that moved fast, which cloud title exactly when you need to assert. Fee lapses hiding inside the list, where assets being sold are already dead. And claim-product mismatch, where the portfolio describes the seller's technology vision rather than anything shipping in the market you are buying into.
Every one of these is findable in diligence, and each is dramatically cheaper to find before the price is set. The title and encumbrance work belongs to your counsel; the claim mapping and landscape positioning is analyst work; the deal team needs both reports on the same table.
Valuation comes after diligence, not before
Price the portfolio that survives the six checks, not the portfolio in the data room. Once diligence establishes what is real, valuation triangulates licensing income, market comparables, and a brokered-market floor against the assets that passed. We have built acquisition-grade valuations for more than 25 years, and our ipValue Model has supported over $2 billion in cumulative transaction value; for ranges and tiers, our patent valuation cost guide covers what transaction-grade work involves.
As a consultancy we evaluate the business and competitive substance and work alongside your deal counsel, who owns the legal opinions. We hold no stake in whether the transaction closes, which is exactly what you want from the people telling you what the assets are worth.
Related questions
What documents should we request from the seller?
The full docket with family relationships and fee status, all assignment records, prosecution histories for key assets, every license and security agreement touching the portfolio, litigation and challenge history, and any standards-body declarations. Reluctance to produce the license agreements is itself a finding.
Do we need both lawyers and consultants for this?
For a deal of any size, yes, because the failure modes differ. Counsel catches title defects, encumbrances, and validity exposure. Analysts catch the business problems: claims that cover nothing in the market, weak competitive position, and inflated valuations. Each half routinely finds what the other cannot.
How is the price usually negotiated?
Against comparables and the income the assets can support, asset by asset for small deals and tier by tier for large ones. Published market data is thin and scattered, which is why documented evidence of use and claim mapping move price more than any industry rule of thumb.
What red flags should kill a deal?
Unfixable title defects on the core assets, a cross-license that already frees your main competitor, crown-jewel claims that clearly read on prior art, and a seller unwilling to disclose encumbrances. Most other findings adjust price; these change whether the asset is worth having.
Know what you are buying before you price it
We can scope claim mapping, landscape positioning, and valuation to your deal timeline, and we work compressed calendars regularly. The discovery call is free.
Talk with Our TeamRelated
ipCapital Group is a consultancy, not a law firm, and nothing on this page is legal advice. Dollar figures on this page are typical market ranges for professional IP services, drawn from published sources and industry experience across a variety of providers. They are not an ipCG quote or rate card; every ipCG engagement is individually scoped and priced. See how our pricing works.